Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
← catalyst calendarNCT07764978 · readout in 876 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
750estimated
Sites
124
Countries
Australia, Brazil, Canada +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-26 | actual | When the study began enrolling |
| Primary completion | 2029-01-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2034-05-12 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Newly Diagnosed Multiple Myeloma
Interventions
- Biological: AZD0120
- Biological: Daratumumab
- Drug: Dexamethasone
- Biological: Isatuximab
- Drug: Lenalidomide
- Drug: Bortezomib
- Drug: Cyclophosphamide
- Drug: Fludarabine
Primary outcomes
what the primary-completion date above is the date OFPFS in NDMM who are ineligible to receive ASCT is measured to demonstrate the superiority of IsaVRd or DRd induction followed by AZD0120 compared to IsaVRd or DRd induction followed by continuous DRd or IsaRd.
measured Up to 9 years.
MRD negative CR rate at 9M in NDMM who are ineligible to receive ASCT is measured to demonstrate the superiority of IsaVRd or DRd induction followed by AZD0120 compared to IsaVRd or DRd induction followed by continuous DRd or IsaRd
measured Up to 9 years.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed